

OHRENBLICK!

Moderne ZytOralia, die über CYP3A4 metabolisiert werden



INN	Metabolisierung
Afatinib	kaum
Alectinib	CYP3A4/5; (1A2, 2C19)
Axitinib	CYP3A4/5; (1A2, 2C19)
Bosutinib	CYP3A4
Cabozantinib	CYP3A4 (CYP2C9)
Ceritinib	CYP3A4
Cobimetinib	CYP3A4
Crizotinib	CYP3A4/5
Dabrafrenib	CYP2C8, 3A4
Dasatinib	CYP3A4
Erlotinib	CYP3A4, 1A1, 1A2
Everolimus	CYP3A4
Gefitinib	CYP3A4, 2D6
Ibrutinib	CYP3A; (2D6)
Idelalisib	CYP3A4
Imatinib	CYP3A4
Ixazomib	CYP3A4 (42%), 1A2 (26%), 2B6 (16%), 2C8 (6%), 2D6 (5%), 2C19 (5%), 2C9 (< 1%)
Lapatinib	CYP3A4/5, 2C8, 2C19
Lenvatinib	CYP3A4 + nicht-enzymatisch
Nilotinib	CYP3A4
Nitedanib	kaum (CYP3A4), hydrolytische Spaltung
Osimertinib	CYP3A4, Dealkylierung
Palbociclib	CYP3A4, SULT2A1
Panobinostat	CYP3A4 (2D6, 2C19)
Pazopanib	CYP3A4, (1A2, 2C8)
Ponatinib	CYP3A4/5, (2C8, 2D6)
Regorafenib	CYP3A4, UGT1A9
Sorafenib	CYP3A4
Sunitinib	CYP3A4
Temsirolimus	CYP3A4
Trametinib	Deacetylierung +/- Monooxygenierung +/- Glucuronidierung, (CYP3A4)
Vandetanib	CYP3A4, FMO1 und -3
Vemurafenib	CYP3A4
Venetoclax	CYP3A4
Vismodegib	(CYP2C9, CYP3A4/5)